Edition:
United States

Krystal Biotech Inc (KRYS.OQ)

KRYS.OQ on NASDAQ Stock Exchange Capital Market

9.35USD
25 Apr 2018
Change (% chg)

$0.25 (+2.75%)
Prev Close
$9.10
Open
$9.04
Day's High
$9.35
Day's Low
$9.00
Volume
802
Avg. Vol
3,727
52-wk High
$11.98
52-wk Low
$8.03

Latest Key Developments (Source: Significant Developments)

Krystal Submits Investigational New Drug (Ind) Application For KB103
Tuesday, 27 Mar 2018 08:00am EDT 

March 27 (Reuters) - Krystal Biotech Inc ::KRYSTAL SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KB103, TOPICAL GENE THERAPY CANDIDATE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA.KRYSTAL BIOTECH - THERAPEUTIC CANDIDATE FORMULATED INTO A TOPICAL GEL FOR DIRECT APPLICATION ONTO SKIN.  Full Article

Krystal Biotech Reports 2017 Financial Results And Business Progress
Monday, 12 Mar 2018 08:00am EDT 

March 12 (Reuters) - Krystal Biotech Inc ::KRYSTAL BIOTECH REPORTS 2017 FINANCIAL RESULTS AND BUSINESS PROGRESS.  Full Article

Krystal Biotech reports qtrly loss per share $1.26‍​
Monday, 13 Nov 2017 04:01pm EST 

Nov 13 (Reuters) - Krystal Biotech Inc :Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results.Krystal Biotech Inc qtrly loss per share $1.26‍​.Krystal Biotech Inc - ‍Currently preparing to file an investigational drug application for KB103 in Q1 of 2018​.  Full Article

Krystal Biotech says KB103 granted orphan drug designation by FDA
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - Krystal Biotech Inc :Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa.Krystal Biotech Inc - on track to file IND for KB103 in Q1 2018​.  Full Article

Krystal Biotech shares open at 5 pct above IPO price
Wednesday, 20 Sep 2017 12:16pm EDT 

Sept 20 (Reuters) - :Krystal Biotech Inc shares open at $10.50 in debut on the NASDAQ versus IPO price of $10.00 per share.  Full Article

BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍​

* Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results